Thursday 23 May, Royal Marsden Hospital London
1-day course: Targeted Treatments for Cancers of the Digestive System
Level: Intermediate/Advanced
Audience: Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
Description: In this course I describe the faulty genes, pathways and proteins that drive colorectal, head and neck, pancreatic, oesophageal, gastric and primary liver cancer. I also explain the science behind many targeted treatment approaches for these diseases, including EGFR- and HER2-targeted antibodies, angiogenesis inhibitors and immunotherapy with checkpoint inhibitors.
To book, contact: conferenceteam@rmh.nhs.uk
Programme
An introduction to cancer biology and genetics
- Linking DNA damage to cancer development
- Epigenetics – altering gene expression without genetic mutation
- Cancer cells and their microenvironment
- An introduction to cell signalling
- Genetic instability and intra-tumoural heterogeneity
- Monoclonal antibodies and kinase inhibitors: spot the difference
- The genesis of colorectal cancer
- Chromosomal instability phenotype
- Microsatellite instability (MSI) and CpG island methylator phenotype (CIMP)
- EGFR targeted treatments
- Angiogenesis inhibitors
- Immunotherapy for MSI- high colorectal cancer
Targeted treatments for head and neck, oesophageal and stomach cancer
- Cellular & molecular makeup: adenocarcinoma vs. squamous cell carcinoma
- EGFR and HER2 targeted treatments
- Angiogenesis inhibitors
- Immunotherapy with checkpoint inhibitors
Targeted treatments for pancreatic cancer and primary liver cancer
- The molecular and cellular makeup of pancreatic cancer
- A few dead ends and current approaches in UK trials
- The molecular and cellular makeup of primary liver cancer
- Current and future approaches to targeted treatments for liver cancer